New Releases from NCBI BookshelfExagamglogene Autotemcel (Casgevy): Indication: For the treatment of patients 12 years of age and older with sickle cell disease with recurrent vaso-occlusive crises: Reimbursement Recommendation [Internet].​Exagamglogene Autotemcel (Casgevy): Indication: For the treatment of patients 12 years of age and older with sickle cell disease with recurrent vaso-occlusive crises: Reimbursement Recommendation [Internet].

By /

Canada’s Drug Agency (CDA-AMC) recommends that Casgevy be reimbursed by public drug plans for the treatment of sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs), if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top